IntronBio Secures Efficacy for CDI Intestinal Disease Treatment Clinical Isolate Strain

[Asia Economy Reporter Hyungsoo Park] Intronbio announced on the 12th that it confirmed excellent efficacy of the clinical isolates against the biopharmaceutical candidate CDL200, a treatment for refractory and recurrent intestinal disease (CDI).

Antimicrobial activity of CDL200 was evaluated against 20 clinical isolates obtained from patients in Europe and Korea. It was confirmed that CDL200 exhibited a strong bacteriolytic effect within minutes (1 to 5 minutes) against all tested strains. Among the tested strains, many were resistant to existing antibiotics such as metronidazole, vancomycin, and rifaximin.

CDL200 is an endolysin new drug substance used to treat Clostridioides difficile infection, one of the refractory and recurrent intestinal diseases. CDL200 eradicates bacteria faster than existing antibiotics. It can also be used to treat infectious diseases caused by antibiotic-resistant or highly virulent bacteria.

Kang Sanghyun, head of research at Intronbio, said, "We are pursuing securing a biopharmaceutical pipeline that can respond to infectious diseases urgently requiring effective treatments, including CDI," adding, "The pipeline is based on endolysins applied with itLysin technology, a specialized technology unique to Intronbio."

Yoon Kyungwon, CEO of Intronbio, added, "Based on the experience of developing SAL200, we will strive to enhance the value of the subsequent pipeline," and "We will continue efforts to secure global competitiveness in the endolysin field."

This content was produced with the assistance of AI translation services.